Loading…

Optimization of the Pharmacokinetic Profile of [ 99m Tc]Tc-N 4 -Bombesin Derivatives by Modification of the Pharmacophoric Gln-Trp Sequence

Current radiolabeled gastrin-releasing peptide receptor (GRPR) ligands usually suffer from high accumulation in GRPR-positive organs (pancreas, stomach), limiting tumor-to-background contrast in the abdomen. In novel N4-bombesin derivatives this was addressed by substitutions at the Gln7-Trp8 site w...

Full description

Saved in:
Bibliographic Details
Published in:Pharmaceuticals (Basel, Switzerland) Switzerland), 2022-09, Vol.15 (9)
Main Authors: Günther, Thomas, Konrad, Matthias, Stopper, León, Kunert, Jan-Philip, Fischer, Sebastian, Beck, Roswitha, Casini, Angela, Wester, Hans-Jürgen
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page
container_issue 9
container_start_page
container_title Pharmaceuticals (Basel, Switzerland)
container_volume 15
creator Günther, Thomas
Konrad, Matthias
Stopper, León
Kunert, Jan-Philip
Fischer, Sebastian
Beck, Roswitha
Casini, Angela
Wester, Hans-Jürgen
description Current radiolabeled gastrin-releasing peptide receptor (GRPR) ligands usually suffer from high accumulation in GRPR-positive organs (pancreas, stomach), limiting tumor-to-background contrast in the abdomen. In novel N4-bombesin derivatives this was addressed by substitutions at the Gln7-Trp8 site within the MJ9 peptide (H-Pip5-phe6-Gln7-Trp8-Ala9-Val10-Gly11-His12-Sta13-Leu14-NH2) either by homoserine (Hse7), β-(3-benzothienyl) alanine (Bta8) or α-methyl tryptophan (α-Me-Trp8), with the aim of optimizing pharmacokinetics. We prepared and characterized the peptide conjugates 6-carboxy-1,4,8,11-tetraazaundecane (N4)-asp-MJ9, N4-asp-[Bta8]MJ9, N4-[Hse7]MJ9 and N4-[α-Me-Trp8]MJ9, and evaluated these compounds in vitro (GRPR affinity via IC50,inverse; internalization; lipophilicity via logD7.4) and in vivo (biodistribution and μSPECT/CT studies at 1 h post injection (p.i.) in PC-3 tumor-bearing CB17-SCID mice). 99mTc-labeling resulted in radiochemical yields (RCYs) > 95%. All 99mTc-labeled MJ9 analogues showed comparable or higher GRPR affinity than the external reference [99mTc]Tc-Demobesin 4. Receptor-bound fractions were noticeably higher than that of the reference. Despite a slightly enhanced lipophilicity, all novel MJ9 derivatives revealed improved in vivo pharmacokinetics compared to the reference. The Bta8-modified ligand revealed the most favorable tumor-to-abdomen contrast at 1 h p.i. Substitutions at the Gln7-Trp8 site within GRPR ligands hold great potential to modify pharmacokinetics for improved imaging.
doi_str_mv 10.3390/ph15091133
format article
fullrecord <record><control><sourceid>pubmed</sourceid><recordid>TN_cdi_pubmed_primary_36145354</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>36145354</sourcerecordid><originalsourceid>FETCH-LOGICAL-p108t-fec53731ad14f2f93fb6db1abd3c72e2af90f077f4d1e0df72b2f69993cb22683</originalsourceid><addsrcrecordid>eNpt0E1KAzEABeAgiq3VjQeQXGA0fzOZLLVqFaotOK5ESn6ZaGcSM9NCvYKXtqKCC1fvwYNv8QA4xuiUUoHOYo1zJDCmdAcMMSMsKwnju3_6ABx03QtCOccM74MBLTDLac6G4GMWe9_4d9n70MLgYF9bOK9laqQOr761vddwnoLzS_s1P0EhGljp50pn95DB7CI0yna-hZc2-fWWWdsOqg28C8Y7r_91Yx3Slp0s26xKET7Yt5VttT0Ee04uO3v0kyPweH1VjW-y6WxyOz6fZhGjss-c1TnlFEuDmSNOUKcKo7BUhmpOLJFOIIc4d8xgi4zjRBFXCCGoVoQUJR2Bk283rlRjzSIm38i0Wfy-Qj8B8ARk8w</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Optimization of the Pharmacokinetic Profile of [ 99m Tc]Tc-N 4 -Bombesin Derivatives by Modification of the Pharmacophoric Gln-Trp Sequence</title><source>PubMed (Medline)</source><source>Publicly Available Content (ProQuest)</source><creator>Günther, Thomas ; Konrad, Matthias ; Stopper, León ; Kunert, Jan-Philip ; Fischer, Sebastian ; Beck, Roswitha ; Casini, Angela ; Wester, Hans-Jürgen</creator><creatorcontrib>Günther, Thomas ; Konrad, Matthias ; Stopper, León ; Kunert, Jan-Philip ; Fischer, Sebastian ; Beck, Roswitha ; Casini, Angela ; Wester, Hans-Jürgen</creatorcontrib><description>Current radiolabeled gastrin-releasing peptide receptor (GRPR) ligands usually suffer from high accumulation in GRPR-positive organs (pancreas, stomach), limiting tumor-to-background contrast in the abdomen. In novel N4-bombesin derivatives this was addressed by substitutions at the Gln7-Trp8 site within the MJ9 peptide (H-Pip5-phe6-Gln7-Trp8-Ala9-Val10-Gly11-His12-Sta13-Leu14-NH2) either by homoserine (Hse7), β-(3-benzothienyl) alanine (Bta8) or α-methyl tryptophan (α-Me-Trp8), with the aim of optimizing pharmacokinetics. We prepared and characterized the peptide conjugates 6-carboxy-1,4,8,11-tetraazaundecane (N4)-asp-MJ9, N4-asp-[Bta8]MJ9, N4-[Hse7]MJ9 and N4-[α-Me-Trp8]MJ9, and evaluated these compounds in vitro (GRPR affinity via IC50,inverse; internalization; lipophilicity via logD7.4) and in vivo (biodistribution and μSPECT/CT studies at 1 h post injection (p.i.) in PC-3 tumor-bearing CB17-SCID mice). 99mTc-labeling resulted in radiochemical yields (RCYs) &gt; 95%. All 99mTc-labeled MJ9 analogues showed comparable or higher GRPR affinity than the external reference [99mTc]Tc-Demobesin 4. Receptor-bound fractions were noticeably higher than that of the reference. Despite a slightly enhanced lipophilicity, all novel MJ9 derivatives revealed improved in vivo pharmacokinetics compared to the reference. The Bta8-modified ligand revealed the most favorable tumor-to-abdomen contrast at 1 h p.i. Substitutions at the Gln7-Trp8 site within GRPR ligands hold great potential to modify pharmacokinetics for improved imaging.</description><identifier>ISSN: 1424-8247</identifier><identifier>EISSN: 1424-8247</identifier><identifier>DOI: 10.3390/ph15091133</identifier><identifier>PMID: 36145354</identifier><language>eng</language><publisher>Switzerland</publisher><ispartof>Pharmaceuticals (Basel, Switzerland), 2022-09, Vol.15 (9)</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><orcidid>0000-0003-1599-9542 ; 0000-0001-6149-7119 ; 0000-0002-7412-0297 ; 0000-0002-3914-842X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36145354$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Günther, Thomas</creatorcontrib><creatorcontrib>Konrad, Matthias</creatorcontrib><creatorcontrib>Stopper, León</creatorcontrib><creatorcontrib>Kunert, Jan-Philip</creatorcontrib><creatorcontrib>Fischer, Sebastian</creatorcontrib><creatorcontrib>Beck, Roswitha</creatorcontrib><creatorcontrib>Casini, Angela</creatorcontrib><creatorcontrib>Wester, Hans-Jürgen</creatorcontrib><title>Optimization of the Pharmacokinetic Profile of [ 99m Tc]Tc-N 4 -Bombesin Derivatives by Modification of the Pharmacophoric Gln-Trp Sequence</title><title>Pharmaceuticals (Basel, Switzerland)</title><addtitle>Pharmaceuticals (Basel)</addtitle><description>Current radiolabeled gastrin-releasing peptide receptor (GRPR) ligands usually suffer from high accumulation in GRPR-positive organs (pancreas, stomach), limiting tumor-to-background contrast in the abdomen. In novel N4-bombesin derivatives this was addressed by substitutions at the Gln7-Trp8 site within the MJ9 peptide (H-Pip5-phe6-Gln7-Trp8-Ala9-Val10-Gly11-His12-Sta13-Leu14-NH2) either by homoserine (Hse7), β-(3-benzothienyl) alanine (Bta8) or α-methyl tryptophan (α-Me-Trp8), with the aim of optimizing pharmacokinetics. We prepared and characterized the peptide conjugates 6-carboxy-1,4,8,11-tetraazaundecane (N4)-asp-MJ9, N4-asp-[Bta8]MJ9, N4-[Hse7]MJ9 and N4-[α-Me-Trp8]MJ9, and evaluated these compounds in vitro (GRPR affinity via IC50,inverse; internalization; lipophilicity via logD7.4) and in vivo (biodistribution and μSPECT/CT studies at 1 h post injection (p.i.) in PC-3 tumor-bearing CB17-SCID mice). 99mTc-labeling resulted in radiochemical yields (RCYs) &gt; 95%. All 99mTc-labeled MJ9 analogues showed comparable or higher GRPR affinity than the external reference [99mTc]Tc-Demobesin 4. Receptor-bound fractions were noticeably higher than that of the reference. Despite a slightly enhanced lipophilicity, all novel MJ9 derivatives revealed improved in vivo pharmacokinetics compared to the reference. The Bta8-modified ligand revealed the most favorable tumor-to-abdomen contrast at 1 h p.i. Substitutions at the Gln7-Trp8 site within GRPR ligands hold great potential to modify pharmacokinetics for improved imaging.</description><issn>1424-8247</issn><issn>1424-8247</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNpt0E1KAzEABeAgiq3VjQeQXGA0fzOZLLVqFaotOK5ESn6ZaGcSM9NCvYKXtqKCC1fvwYNv8QA4xuiUUoHOYo1zJDCmdAcMMSMsKwnju3_6ABx03QtCOccM74MBLTDLac6G4GMWe9_4d9n70MLgYF9bOK9laqQOr761vddwnoLzS_s1P0EhGljp50pn95DB7CI0yna-hZc2-fWWWdsOqg28C8Y7r_91Yx3Slp0s26xKET7Yt5VttT0Ee04uO3v0kyPweH1VjW-y6WxyOz6fZhGjss-c1TnlFEuDmSNOUKcKo7BUhmpOLJFOIIc4d8xgi4zjRBFXCCGoVoQUJR2Bk283rlRjzSIm38i0Wfy-Qj8B8ARk8w</recordid><startdate>20220910</startdate><enddate>20220910</enddate><creator>Günther, Thomas</creator><creator>Konrad, Matthias</creator><creator>Stopper, León</creator><creator>Kunert, Jan-Philip</creator><creator>Fischer, Sebastian</creator><creator>Beck, Roswitha</creator><creator>Casini, Angela</creator><creator>Wester, Hans-Jürgen</creator><scope>NPM</scope><orcidid>https://orcid.org/0000-0003-1599-9542</orcidid><orcidid>https://orcid.org/0000-0001-6149-7119</orcidid><orcidid>https://orcid.org/0000-0002-7412-0297</orcidid><orcidid>https://orcid.org/0000-0002-3914-842X</orcidid></search><sort><creationdate>20220910</creationdate><title>Optimization of the Pharmacokinetic Profile of [ 99m Tc]Tc-N 4 -Bombesin Derivatives by Modification of the Pharmacophoric Gln-Trp Sequence</title><author>Günther, Thomas ; Konrad, Matthias ; Stopper, León ; Kunert, Jan-Philip ; Fischer, Sebastian ; Beck, Roswitha ; Casini, Angela ; Wester, Hans-Jürgen</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p108t-fec53731ad14f2f93fb6db1abd3c72e2af90f077f4d1e0df72b2f69993cb22683</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Günther, Thomas</creatorcontrib><creatorcontrib>Konrad, Matthias</creatorcontrib><creatorcontrib>Stopper, León</creatorcontrib><creatorcontrib>Kunert, Jan-Philip</creatorcontrib><creatorcontrib>Fischer, Sebastian</creatorcontrib><creatorcontrib>Beck, Roswitha</creatorcontrib><creatorcontrib>Casini, Angela</creatorcontrib><creatorcontrib>Wester, Hans-Jürgen</creatorcontrib><collection>PubMed</collection><jtitle>Pharmaceuticals (Basel, Switzerland)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Günther, Thomas</au><au>Konrad, Matthias</au><au>Stopper, León</au><au>Kunert, Jan-Philip</au><au>Fischer, Sebastian</au><au>Beck, Roswitha</au><au>Casini, Angela</au><au>Wester, Hans-Jürgen</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Optimization of the Pharmacokinetic Profile of [ 99m Tc]Tc-N 4 -Bombesin Derivatives by Modification of the Pharmacophoric Gln-Trp Sequence</atitle><jtitle>Pharmaceuticals (Basel, Switzerland)</jtitle><addtitle>Pharmaceuticals (Basel)</addtitle><date>2022-09-10</date><risdate>2022</risdate><volume>15</volume><issue>9</issue><issn>1424-8247</issn><eissn>1424-8247</eissn><abstract>Current radiolabeled gastrin-releasing peptide receptor (GRPR) ligands usually suffer from high accumulation in GRPR-positive organs (pancreas, stomach), limiting tumor-to-background contrast in the abdomen. In novel N4-bombesin derivatives this was addressed by substitutions at the Gln7-Trp8 site within the MJ9 peptide (H-Pip5-phe6-Gln7-Trp8-Ala9-Val10-Gly11-His12-Sta13-Leu14-NH2) either by homoserine (Hse7), β-(3-benzothienyl) alanine (Bta8) or α-methyl tryptophan (α-Me-Trp8), with the aim of optimizing pharmacokinetics. We prepared and characterized the peptide conjugates 6-carboxy-1,4,8,11-tetraazaundecane (N4)-asp-MJ9, N4-asp-[Bta8]MJ9, N4-[Hse7]MJ9 and N4-[α-Me-Trp8]MJ9, and evaluated these compounds in vitro (GRPR affinity via IC50,inverse; internalization; lipophilicity via logD7.4) and in vivo (biodistribution and μSPECT/CT studies at 1 h post injection (p.i.) in PC-3 tumor-bearing CB17-SCID mice). 99mTc-labeling resulted in radiochemical yields (RCYs) &gt; 95%. All 99mTc-labeled MJ9 analogues showed comparable or higher GRPR affinity than the external reference [99mTc]Tc-Demobesin 4. Receptor-bound fractions were noticeably higher than that of the reference. Despite a slightly enhanced lipophilicity, all novel MJ9 derivatives revealed improved in vivo pharmacokinetics compared to the reference. The Bta8-modified ligand revealed the most favorable tumor-to-abdomen contrast at 1 h p.i. Substitutions at the Gln7-Trp8 site within GRPR ligands hold great potential to modify pharmacokinetics for improved imaging.</abstract><cop>Switzerland</cop><pmid>36145354</pmid><doi>10.3390/ph15091133</doi><orcidid>https://orcid.org/0000-0003-1599-9542</orcidid><orcidid>https://orcid.org/0000-0001-6149-7119</orcidid><orcidid>https://orcid.org/0000-0002-7412-0297</orcidid><orcidid>https://orcid.org/0000-0002-3914-842X</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1424-8247
ispartof Pharmaceuticals (Basel, Switzerland), 2022-09, Vol.15 (9)
issn 1424-8247
1424-8247
language eng
recordid cdi_pubmed_primary_36145354
source PubMed (Medline); Publicly Available Content (ProQuest)
title Optimization of the Pharmacokinetic Profile of [ 99m Tc]Tc-N 4 -Bombesin Derivatives by Modification of the Pharmacophoric Gln-Trp Sequence
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T16%3A40%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Optimization%20of%20the%20Pharmacokinetic%20Profile%20of%20%5B%2099m%20Tc%5DTc-N%204%20-Bombesin%20Derivatives%20by%20Modification%20of%20the%20Pharmacophoric%20Gln-Trp%20Sequence&rft.jtitle=Pharmaceuticals%20(Basel,%20Switzerland)&rft.au=G%C3%BCnther,%20Thomas&rft.date=2022-09-10&rft.volume=15&rft.issue=9&rft.issn=1424-8247&rft.eissn=1424-8247&rft_id=info:doi/10.3390/ph15091133&rft_dat=%3Cpubmed%3E36145354%3C/pubmed%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-p108t-fec53731ad14f2f93fb6db1abd3c72e2af90f077f4d1e0df72b2f69993cb22683%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/36145354&rfr_iscdi=true